Explore

Trendline Trendline
Rocket Pharmaceuticals Reports Financial Results and Advances Gene Therapy Pipeline

Rocket Pharmaceuticals Reports Financial Results and Advances Gene Therapy Pipeline

Rocket Pharmaceuticals Reports Financial Results and Advances Gene Therapy Pipeline
Trendline Trendline
Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives
Trendline Trendline
Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments

Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments

Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments
Trendline Trendline
enGene Reports Promising Interim Results for Bladder Cancer Gene Therapy Trial

enGene Reports Promising Interim Results for Bladder Cancer Gene Therapy Trial

enGene Reports Promising Interim Results for Bladder Cancer Gene Therapy Trial
Trendline Trendline
Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD

Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD

Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD
Trendline Trendline
Sarepta Therapeutics Urges Caution in Expectations for Elevidys Recovery Amidst FDA Restrictions

Sarepta Therapeutics Urges Caution in Expectations for Elevidys Recovery Amidst FDA Restrictions

Sarepta Therapeutics Urges Caution in Expectations for Elevidys Recovery Amidst FDA Restrictions
Trendline Trendline
Sarepta Therapeutics Reports Strong Q1 2026 Financial Results and Advances in Genetic Medicine

Sarepta Therapeutics Reports Strong Q1 2026 Financial Results and Advances in Genetic Medicine

Sarepta Therapeutics Reports Strong Q1 2026 Financial Results and Advances in Genetic Medicine
Trendline Trendline
Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway

Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway

Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy

Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy

Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy